NovaBay Pharmaceuticals Inc. (NBY) - Market Cap to Earnings

NovaBay Pharmaceuticals Inc. - graphic logo of issuer NBY

This daily price chart for NovaBay Pharmaceuticals (NBY) reflects the dynamics of a company with a P/E of -6.50. The business relies on stable, non-cyclical demand for ocular hygiene products. The Avenova brand enjoys unconditional recognition among physicians due to the sterility of its products. Management is currently reducing revenue concentration risks by introducing skin regeneration product lines.

NBY NovaBay Pharmaceuticals Inc.: P/E Multiple in the range 07/04/2022 - 04/18/2026

Analytical breakdowns for NovaBay Pharmaceuticals

Comprehensive company analysis:NBY (NovaBay)
Manufactured product of novabay.com

For NovaBay Pharmaceuticals, a leader in the Avenova sterile eye hygiene segment, the current price-to-earnings valuation of -6.50 reflects market expectations regarding the monetization of its ophthalmological innovations. This ratio, calculated as market capitalization divided by net income, measures the cost of one dollar of earnings, allowing investors to identify asset overvaluation or the hidden risks of an unjustifiably low multiple.